{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:01:37Z","timestamp":1789704097830,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40264-022-01235-7","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T21:23:01Z","timestamp":1663968181000},"page":"1403-1411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink"],"prefix":"10.1007","volume":"45","author":[{"given":"Rebecca","family":"Persson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Cordey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-1067","authenticated-orcid":false,"given":"Susan","family":"Jick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"1235_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/176298","volume":"2012","author":"P Lloyd","year":"2012","unstructured":"Lloyd P, Ryan C, Menter A. Psoriatic arthritis: an update. Arthritis. 2012;2012: 176298.","journal-title":"Arthritis"},{"key":"1235_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496\u2013509.","journal-title":"N Engl J Med"},{"key":"1235_CR3","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3899\/jrheum.081015","volume":"36","author":"JA Singh","year":"2009","unstructured":"Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol. 2009;36:1012\u201320.","journal-title":"J Rheumatol"},{"key":"1235_CR4","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583\u201390.","journal-title":"Biochem Pharmacol"},{"key":"1235_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"1235_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387\u201399.","journal-title":"Br J Dermatol"},{"key":"1235_CR7","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Myerson GE, Fleischmann RM, Liot\u00e9 F, D\u00edaz-Gonz\u00e1lez F, Van den Bosch F, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 Trial. J Rheumatol. 2016;43:1724\u201334.","journal-title":"J Rheumatol"},{"key":"1235_CR8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065\u201373.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR10","unstructured":"EMA. Otezla: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf. Accessed 5 Nov 2021."},{"key":"1235_CR11","unstructured":"NICE. Apremilast for treating moderate to severe plaque psoriasis. Technology appraisal guidance. https:\/\/www.nice.org.uk\/guidance\/ta419\/resources\/apremilast-for-treating-moderate-to-severe-plaque-psoriasis-pdf-82604611623877. Accessed 5 Nov 2021."},{"key":"1235_CR12","unstructured":"NICE. Apremilast for treating active psoriatic arthritis. https:\/\/www.nice.org.uk\/guidance\/ta433\/resources\/apremilast-for-treating-active-psoriatic-arthritis-pdf-82604722478533. Accessed 3 Nov 2021."},{"key":"1235_CR13","unstructured":"CPRD. A longitudinal safety study of patients with psoriasis and psoriatic arthritis treated with either Otezla (apremilast) or a comparator drug. https:\/\/cprd.com\/protocol\/longitudinal-safety-study-patients-psoriasis-and-psoriatic-arthritis-treated-either-otezla. Accessed 3 Nov 2021."},{"key":"1235_CR14","doi-asserted-by":"publisher","unstructured":"Clinical Practice Research Datalink. CPRD GOLD February 2021 (version 2021.02.001). https:\/\/doi.org\/10.48329\/S0M3-8M14. Accessed 3 Nov 2021.","DOI":"10.48329\/S0M3-8M14"},{"key":"1235_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, Van Staa T, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44:827\u201336.","journal-title":"Int J Epidemiol"},{"key":"1235_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","volume":"69","author":"E Herrett","year":"2010","unstructured":"Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69:4\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"1235_CR17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1592\/phco.23.5.686.32205","volume":"23","author":"SS Jick","year":"2003","unstructured":"Jick SS, Kaye JA, Vasilakis-Scaramozza C, Rodr\u00edguez LAG, Ruig\u00f3mez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23:686\u20139.","journal-title":"Pharmacotherapy"},{"key":"1235_CR18","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.3399\/bjgp10X483562","volume":"60","author":"NF Khan","year":"2010","unstructured":"Khan NF, Harrison SE, Rosme PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60:e128\u201336.","journal-title":"Br J Gen Pract"},{"key":"1235_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3899\/jrheum.140647","volume":"42","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42:479\u201388.","journal-title":"J Rheumatol"},{"key":"1235_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12869","volume":"2","author":"VL Bartlett","year":"2019","unstructured":"Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw Open. 2019;2: e1912869.","journal-title":"JAMA Netw Open"},{"key":"1235_CR21","first-page":"370","volume":"23","author":"W Malatestinic","year":"2017","unstructured":"Malatestinic W, Nordstrom B, Wu JJ, Goldblum O, Solotkin K, Lin CY, et al. Characteristics and medication use of psoriasis patients who may or may not qualify for randomized controlled trials. J Manag Care Spec Pharm. 2017;23:370\u201381.","journal-title":"J Manag Care Spec Pharm"},{"key":"1235_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","volume":"154","author":"KJ Mason","year":"2018","unstructured":"Mason KJ, Barker J, Smith CH, Hampton PJ, Lunt M, McElhone K, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154:581\u20138.","journal-title":"JAMA Dermatol"},{"key":"1235_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jaad.2020.03.043","volume":"83","author":"R Persson","year":"2020","unstructured":"Persson R, Hagberg KW, Qian Y, Vasilakis-Scaramozza C, Jick S. The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: a cohort study in the US MarketScan database. J Am Acad Dermatol. 2020;83:271\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"1235_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1901-3","volume":"21","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1\u20133 pooled analysis. Arthritis Res Ther. 2019;21:1\u20138.","journal-title":"Arthritis Res Ther"},{"key":"1235_CR25","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamadermatol.2019.1121","volume":"155","author":"ED Dommasch","year":"2019","unstructured":"Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol. 2019;155:1142\u201352.","journal-title":"JAMA Dermatol"},{"key":"1235_CR26","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","volume":"157","author":"L Penso","year":"2021","unstructured":"Penso L, Dray-Spira R, Weill A, Pina Vegas L, Zureik M, Sbidian E. Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol. 2021;157:1056\u201365.","journal-title":"JAMA Dermatol"},{"key":"1235_CR27","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","volume":"65","author":"M Wakkee","year":"2011","unstructured":"Wakkee M, de Vries E, van den Haak P, Nijsten T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol. 2011;65:1135\u201344.","journal-title":"J Am Acad Dermatol"},{"key":"1235_CR28","unstructured":"Otezla. Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/3648\/smpc. Accessed 3 Nov 2021."},{"key":"1235_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204867","volume":"74","author":"J S\u00f8rensen","year":"2015","unstructured":"S\u00f8rensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2015;74: e12.","journal-title":"Ann Rheum Dis"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01235-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01235-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01235-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T15:55:10Z","timestamp":1665676510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01235-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01235-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"assertion":[{"value":"31 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rebecca Persson received research grants to her institution from Amgen Inc. Myriam  Cordey and Maria Paris are employees of Amgen Inc. Susan Jick received research grants to her institution and is a consultant for Amgen Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is based in part on data from the CPRD obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the National Health Service as part of their care and support. The interpretation and conclusions contained in this study are those of the authors alone. This study was approved by the Independent Scientific Advisory Committee for Medicines and Healthcare products Regulatory Agency database research (protocol no.: 16_083) and registered in the European Union Post-Authorization Studies register (EUPAS11891). The protocol can be made available to the journal\u2019s reviewers upon request. Hospital Episode Statistics Copyright \u00a9 (2020), re-used with the permission of The Health and Social Care Information Centre. All rights reserved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Per our license agreement with CPRD, we cannot make data available. Requests to access data can be made directly to the CPRD.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Raw CPRD data were accessed using the custom Delphi code. Datasets were analyzed using Stata version 15.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Author contributions were as follows: RP (design, electronic record review, analysis, interpretation, manuscript writing, manuscript revision), MC (interpretation, manuscript writing, manuscript revision), MP (design, interpretation, manuscript writing, manuscript revision), SJ (conception, design, electronic record review, acquisition, interpretation, manuscript writing, manuscript revision).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}